AbbVie CEO Upbeat On Skyrizi Commercialization, Raises Financial Guidance

 
• By John Davis

AbbVie’s product pipeline may be delivering just in time to alleviate concerns about loss of exclusivity on its best-selling product, Humira.  

Steps
Product approvals and increasing revenues are buoying AbbVie, but biosimilar concerns with Humira remain • Source: Shutterstock

More from Business

More from Scrip